Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
1 clinical trials · Sponsor
◉ Watch Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (NCT05489731) | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. | 2022-09-21 |
Track Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.